Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1760844

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1760844

Cancer Therapies

PUBLISHED:
PAGES: 590 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Cancer Therapies Market to Reach US$382.0 Billion by 2030

The global market for Cancer Therapies estimated at US$210.5 Billion in the year 2024, is expected to reach US$382.0 Billion by 2030, growing at a CAGR of 10.4% over the analysis period 2024-2030. Blood Cancer, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$119.2 Billion by the end of the analysis period. Growth in the Breast Cancer segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$82.5 Billion While China is Forecast to Grow at 12.9% CAGR

The Cancer Therapies market in the U.S. is estimated at US$82.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$35.3 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.0% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.6% CAGR.

Global Cancer Therapies Market - Key Trends & Drivers Summarized

Cancer therapies have evolved significantly over the past few decades, leading to improved patient outcomes and survival rates. Cancer therapy refers to the treatment of a patient suffering from cancer with therapies such as chemotherapy, targeted therapy, radiation therapy and immunotherapy among others. These treatments target the removal or destruction of cancerous cells. Surgery involves physically removing tumors, while chemotherapy uses potent drugs to kill rapidly dividing cells, and radiation therapy employs high-energy radiation to damage DNA in cancer cells, preventing them from multiplying. Given the side effects associated with these treatments, there has been a continuous search for more targeted and less harmful treatment options.

Recent advancements in cancer therapies have introduced a new era of precision medicine, focusing on treatments that specifically target cancer cells while sparing healthy tissue. Immunotherapy, which leverages the body's immune system to fight cancer, has shown remarkable success in treating various types of cancer. Checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines are some of the innovative immunotherapy approaches that have gained approval in recent years. Additionally, targeted therapies that interfere with specific molecules involved in cancer growth and progression, such as tyrosine kinase inhibitors and monoclonal antibodies, have provided effective treatment options with fewer side effects compared to traditional methods. The advent of personalized medicine, where treatments are tailored based on the genetic profile of the patient’s tumor, has further enhanced the efficacy and safety of cancer therapies.

The growth in the cancer therapies market is driven by several factors. Advances in biotechnology and genomics have led to the development of novel therapies and personalized treatment approaches, significantly expanding the range of options available to patients. The increasing prevalence of cancer worldwide, partly due to aging populations and lifestyle factors, is fueling demand for effective treatments. Moreover, substantial investment in cancer research by pharmaceutical companies and government agencies is accelerating the discovery and development of new therapies. The rising awareness and early diagnosis of cancer are also contributing to market growth, as early-stage cancers are more treatable with modern therapies. Additionally, regulatory approvals of new and innovative treatments are providing more options for patients and clinicians. The expansion of healthcare infrastructure, particularly in emerging economies, is making advanced cancer therapies more accessible to a broader population. Collaborations and partnerships among biotech firms, research institutions, and healthcare providers are fostering innovation and facilitating the commercialization of cutting-edge cancer treatments.

SCOPE OF STUDY:

The report analyzes the Cancer Therapies market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Other Treatment Types); Cancer Type (Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer, Other Cancer Types)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 109 Featured) -

  • AbbVie Inc.
  • Alaunos Therapeutics, Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Celldex Therapeutics, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Glaxosmithkline Plc
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP-1551

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Tariff Impact on Global Supply Chain Patterns
    • Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth in Cancer Therapies Market
    • Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market
    • By Cancer Type
    • Select Cancer Stats
    • Global Economic Update
    • Cancer Therapies - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Research Continues to Unravel Complexities of Cancer
    • Evolution of Oncology Therapeutics: A Three-Decade Perspective on FDA Approvals
    • TABLE : Select Cancer Drugs Approved by FDA in 2023 & 2024
    • Overview of Cancer Therapy Segments
    • Recent Market Activity
    • Influencer/Product/Technology Insights
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Key Advancements in Cancer Treatment to Shape Future Landscape
    • Integration of Stem Cell Research Marks Next Generation of Oncological Therapies
    • Use of Artificial Intelligence for Treating Cancer Patients Witness a Surge
    • Challenges and Future Prospects
    • Immunotherapies to Transform Cancer Care
    • Cancer Immunotherapy Moves to Next Level
    • Potential for CAR T Cell Therapies In Solid Tumors
    • Cancer-on-chip models Gains Attention in immunotherapy
    • Antibody-drug conjugates (ADCS), a Novel Class of Therapeutics Poised to Address the Challenges of Treating Difficult-To-Treat Cancers
    • Novel Drugs & Drug Modifications
    • Chemotherapy Drugs: A Key Weapon in Cancer Treatment
    • Targeted Cancer Therapies: Precision Medicine in Oncology
    • Advances for Precise Tumor Targeting
    • Select Approved Targeted Therapies for Various Types of Cancers
    • Expanding Horizons: The Growth of the Cancer Gene Therapy Market
    • Extending the Success of Cell And Gene Therapy From Blood Cancers To Solid Tumors
    • Vaccines: A Promising Future Area of Cancer Therapeutics
    • Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation
    • Nanovectors: Pioneering the Future of Cancer Treatment
    • Drug Delivery Employing AI and Nanorobots
    • Personalized Medicine Gains Importance
    • Integration of Artificial Intelligence (AI) in Development of Personalized Cancer Treatment: A Novel Approach
    • Increasing Application of Digital Technologies Pave Way for Timely Treatment of Cancer Patients
    • Patent Expiries of Branded Drugs to Trigger Generic Competition
    • Cancer Types, Approved and Pipeline Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Gastrointestinal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Gastrointestinal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Gastrointestinal Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Gynecologic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Gynecologic Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Gynecologic Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 33: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 36: World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 37: World Cancer Therapies Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Cancer Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • CHINA
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Cancer Therapies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Germany 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Italy 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 89: Italy Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Italy Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Italy 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: UK 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 95: UK Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: UK Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: UK 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Spain 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 101: Spain Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Spain Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Spain 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Russia 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 107: Russia Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Russia Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Russia 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Europe 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Asia-Pacific 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Cancer Therapies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Asia-Pacific 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • AUSTRALIA
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Australia 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 128: Australia Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Australia Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Australia 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • INDIA
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 131: India Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: India 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 134: India Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: India Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: India 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: South Korea 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 140: South Korea Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: South Korea Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: South Korea 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Asia-Pacific Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Asia-Pacific 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Latin America 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Latin America 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
    • TABLE 155: Latin America Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 156: Latin America Historic Review for Cancer Therapies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Latin America 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Argentina 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 161: Argentina Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Argentina Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Argentina 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Brazil 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 167: Brazil Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Brazil Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Brazil 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Mexico 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 173: Mexico Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Mexico Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Mexico 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Latin America 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Latin America Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Latin America Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Latin America 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Middle East 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Middle East 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
    • TABLE 188: Middle East Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 189: Middle East Historic Review for Cancer Therapies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Middle East 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • IRAN
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Iran 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 194: Iran Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Iran Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Iran 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Israel 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 200: Israel Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Israel Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Israel 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Saudi Arabia 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 206: Saudi Arabia Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Saudi Arabia Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Saudi Arabia 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: UAE 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 212: UAE Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: UAE Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: UAE 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Rest of Middle East 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 218: Rest of Middle East Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Rest of Middle East Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Rest of Middle East 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030
  • AFRICA
    • Cancer Therapies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Cancer Therapies by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Africa 15-Year Perspective for Cancer Therapies by Treatment Type - Percentage Breakdown of Value Revenues for Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 224: Africa Recent Past, Current & Future Analysis for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types - Independent Analysis of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Africa Historic Review for Cancer Therapies by Cancer Type - Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types Markets - Independent Analysis of Annual Revenues in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Africa 15-Year Perspective for Cancer Therapies by Cancer Type - Percentage Breakdown of Value Revenues for Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Lung Cancer and Other Cancer Types for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!